Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros Inc. (Nasdaq: NEPH) is a commercial-stage medical device and water technology company dedicated to enhancing water quality in both medical and commercial markets. Founded in 1997 by healthcare professionals affiliated with Columbia University Medical Center, Nephros initially aimed to address the needs of chronic renal failure patients. Today, the company is known for its innovative liquid purification filters that capture contaminants as small as 5 nanometers, significantly reducing exposure to a variety of pathogens, including bacteria, viruses, fungi, parasites, and endotoxins.
The heart of Nephros's technology lies in its proprietary hollow fiber design, which balances three critical elements for optimal filter performance: filtration precision, flow rate, and filter lifespan. These filters are highly efficient, providing up to 12 months of service with minimal disruption in flow rate, making them ideal for both healthcare and commercial applications.
In the medical sector, Nephros offers advanced water filtration products and waterborne pathogen detection tools. These products are essential for maintaining high standards of water safety, particularly in healthcare settings where water quality can directly impact patient outcomes. The company's subsidiary is actively working on a second-generation hemodiafiltration system and other devices aimed at improving therapies for renal disease patients.
In the commercial market, Nephros manufactures water filters designed to enhance the taste and odor of water, while also reducing biofilm, bacteria, and scale buildup in downstream equipment. These products cater to a wide range of industries, including hospitality, food service, and manufacturing, where water quality is a critical factor.
Nephros has recently achieved significant milestones, including:
- Filing its third-quarter financial results on November 8, 2023, with a subsequent conference call to discuss the outcomes.
- Hosting investor relations calls to keep stakeholders informed about company developments.
- Continued commitment to providing cutting-edge water filtration solutions and education to improve water safety.
With a mission to improve the human relationship with water, Nephros remains at the forefront of water technology innovation, offering proactive and emergency solutions to ensure water quality across various sectors. For more information, visit the company's website at Nephros.com.
Nephros, Inc. (Nasdaq: NEPH) reported a preliminary revenue of $2.9 million for Q2 2022, marking a 27% increase year-over-year. The number of Active Customer Sites grew by 21% from 1,117 to 1,349. CEO Andy Astor expressed optimism regarding revenue growth, supported by a strong sales pipeline and an expense management plan aimed at achieving positive net cash flow within the next 12 months. The company ended the quarter with approximately $4.2 million in cash. Q2 results will be officially announced on August 10, 2022.
Nephros, Inc. (Nasdaq: NEPH) announced FDA 510(k) clearance for its HDF Assist Module, the first device in the U.S. to provide hemodiafiltration therapy for End-Stage Renal Disease patients. This milestone allows Nephros to enhance treatment options for patients without needing new, expensive equipment. The module will be piloted in select dialysis clinics to establish operational procedures and train staff. Nephros aims to improve water safety through innovative technology, serving both healthcare and commercial sectors.
Nephros, Inc. (NASDAQ: NEPH) reported a net revenue of $2.2 million for Q1 2022, a 20% decrease from the previous year. The company faced a net loss of $2 million, significantly up from $0.5 million in Q1 2021, reflecting a 266% increase in losses. Adjusted EBITDA was (1.5 million), worsened from (0.7 million) last year. Despite these downturns, active customer sites grew 17% year-over-year to 1,276. Nephros withdrew its 2022 revenue guidance due to unexpected market conditions but expressed optimism about future growth.
Nephros, Inc. (Nasdaq: NEPH) will release its first-quarter financial results on May 4, 2022, after market close. A conference call for investors is scheduled for the same day at 4:30 PM ET, with access numbers provided for domestic and international participants. An audio archive of the call will be available shortly after its conclusion. Nephros focuses on water filtration and pathogen detection solutions for healthcare and commercial sectors, promoting water safety through innovative technology.
Nephros has announced a significant rebranding effort aimed at enhancing its integrated approach to water safety. This includes a new logo, messaging, and website, emphasizing the company's mission to improve the relationship between people and water. The rebrand aligns with their commitment to providing filtration solutions and comprehensive support services. CEO Andy Astor highlighted that the new tagline, BECAUSE WATER MATTERS(SM), reflects their dedication to customer education and product accessibility. Additionally, the Nephros Wellspring initiative showcases their investment in social responsibility.
Nephros, Inc. (Nasdaq: NEPH) announced that CEO Andy Astor will present at the 2022 Virtual Growth Conference. The event occurs from March 28th to 30th, starting at 9:00 AM ET on March 28th. Astor's presentation will focus on Nephros's innovations in water safety through pathogen detection and purification solutions for healthcare and commercial markets. The conference, hosted by Maxim Group LLC and M-Vest, features discussions across various sectors including healthcare, clean energy, and technology.
Nephros reported a full-year net revenue of $10.4 million for 2021, reflecting a 22% year-over-year increase. The fourth quarter net revenue reached $2.8 million, up 18% from 2020. For 2022, the company reaffirmed its guidance of $13.0 million to $13.5 million, expecting a growth rate of 25% to 30%. However, the company incurred a net loss of $3.9 million for the year, though this is a 15% improvement from the previous year. The operating loss for the fourth quarter was ($1.0 million), a 37% increase year-over-year. Nephros had approximately $7.0 million in cash as of year-end.
Nephros, a water technology company, announced its plan to release fourth quarter financial results on February 23, 2022. The results will be disclosed after market close, followed by a conference call at 4:30 PM ET. Participants can access the call through domestic and international phone lines. A replay will be available until March 2, 2022. Nephros specializes in innovative filtration and pathogen detection solutions for the healthcare and commercial sectors, emphasizing a commitment to water safety.
RION, a biotechnology company based in Rochester, Minnesota, has appointed Alisa Lask as Chief Commercial Officer. Lask brings extensive experience from leadership roles at major firms including Galderma and Allergan, aiming to commercially leverage RION's groundbreaking exosome therapeutics. The company currently has two active FDA registrations and focuses on innovative biologic platforms for regenerative medicine. Dr. Atta Behfar, RION's founder, expressed confidence in Lask's strategic vision to drive growth in both therapeutic and aesthetic sectors.
Nephros, Inc. (Nasdaq: NEPH) has announced a strong start to 2022, expecting revenue between $13-13.5 million, a projected increase of 25-30% from 2021's $10.4 million. The company attributes its growth to a revamped marketing strategy and new water management standards from CMS. Nephros has seen a 35% increase in facilities using its filters over the past two years and is focused on expanding its pathogen detection systems. The FDA is reviewing its HDF Assist Device, with a commercial launch anticipated in late 2022.
FAQ
What is the current stock price of Nephros (NEPH)?
What is the market cap of Nephros (NEPH)?
What does Nephros Inc. specialize in?
When was Nephros Inc. founded?
What is the core technology of Nephros filters?
What markets does Nephros serve?
What recent achievements has Nephros announced?
How long do Nephros filters last?
How does Nephros contribute to water safety in medical settings?
What is mid-dilution hemodiafiltration (mid-HDF)?
Who are the key contacts for investor relations at Nephros?
Where can I find more information about Nephros?
